Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Pharm304 > Extemporaneous compounding > Flashcards

Extemporaneous compounding Flashcards

1
Q

What is extemporaneous compounding?

A

-manipulation of drugs and chemical ingredients via traditional compounding techniques to produce medications suitable for patients when no commercial forms are appropriate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is off label or unlicensed use?

A
  • the use of medicines outside its product license or approval
  • this can be for the treatment of a different disease or the use of medicine by different population groups
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are the preferred dosage forms for infants 1month - 2 years old?

A

small volumes of liquids

e.g. syrups and solutions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are the preferred dosage forms for children (aged 2-5 years)?

A
  • liquids

- effervescent tablets

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are the preferred dosage forms for children 6-11 years ?

A

-solids like chewable tablets and orally disintegrating tablets

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are the preferred dosage forms for adolescents (12-18 years)

A

-solids, typical adult dosage forms like tablets and capsules

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What are the reasons for compounding?

A
  • required dosage form of a medicine does not exist/is not available
  • allergy sensitivity to an inactive ingredient in manufactured products
  • unavailability or discontinuation of a medicine
  • requirement for different dose, concentration or route of administration
  • novel therapies and specialist products used in hospitals and clinics
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Is compounding accurate?

A

-medicines manufactured by Pharma company will be more of a reliable quality than that compounded in pharmacies due to strict quality control processes and equipment, but sometimes compounding is necessary so we must learn the ground level principles and adapt to the situation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What are the risks assoc with extemporaneous compounding?

A
  • formulation failure due to chemical and physical instability
  • microbial contamination
  • calculation errors
  • patient acceptability issues
  • health and safety risks
  • therapeutic risks and clinical consequence
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are some drugs not available as liquids?

A
  • acetazolamide
  • amlodipine
  • captopril
  • allopurinol
  • lamotrigine
  • omeprazole
  • rifampin
  • topiramate
  • azathioprine
  • levodopa/carbidopa
  • amiodarone
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

How is stability assessed?

A
  • using various storage conditions
  • chemical stability testing by HPLC
  • physical stability testing for appearance, pH, viscosity, microbiology
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What storage conditions should compounded products be tested at?

A
  • fridge: 4 degrees C
  • room temperature: 20 degreesC
  • 40 degrees C/75% RH
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What was the problem with ADHB phenobarbitone oral liquid ?

A
  • contained phenobarbitone pure powder in a mixture of glycerol and water
  • expired in 7 days if refrigerated
  • had problems with stability, short date resulting in frequent compounding
  • had an unacceptable taste leading to non compliance and treatment failure
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What was the result of the phenobarbitone investigation?

A
  • recommended optimal flavour for SP base was lemon 0.75% w/v
  • HOS formulation exp date extended to 6 weeks
  • found to be liquid SP-F stable for 4 weeks (refrigeration optional)
  • better palatability and visocsity properties
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are the good sources of info to go for extemporaneous compounding?

A
  • David Woods website
  • Trissel’s stability of compounded formulations
  • APF
  • International journal of pharmaceutical compounding
  • NZHPA CNO sig
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are the steps to preparing paediatric oral liquids?

A
  1. consider alternative drug
  2. consider alternative method e.g. tablet dispersion or oral admin of injection
  3. consult latest info databases and publications, prepare formulation according to published study and follow conditions as closely as possible. Modifications are only appropriate if there are no detrimental effects on stability
17
Q

What stability information and patient info is require in the preparation of paediatric oral liquids?

A
  • may be possible to adapt existing info from drug stability texts e.g. solubility, pH stability profile, or from the formulation details of the injection or oral liquid available elsewhere
  • provide info to carers to ensure correct use including storage conditions, use of oral syringe, shaking before admin.
18
Q

What are the suspending agents for oral liquid formulation?

A
  • these are preformulated and flavoured suspending agents for insoluble drugs
  • they can be used for bitter tasting drugs due to sweetening effect
  • in NZ we have Ora-Blend, Oral Plus and Ora-sweet
19
Q

What are the neonatal adverse reactions for oral or parenteral benzyl alcohol?

A

-neurotoxicity, metabolic acidosis

20
Q

What are the neonatal adverse reactions for oral or parenteral ethanol?

A

-neurotoxicity

21
Q

What are the neonatal ADRs for parenteral polyethylene glycol?

A

metabolic acidosis

22
Q

What are the neonatal ADRs for parenteral Polysorbate 20 and polysorbate 80?

A

liver and kidney failure

23
Q

What are the neonatal ADRs for oral and parenteral propylene glycol?

A

seizures, neurotoxicity, hypoeromolarity

24
Q

What does Trissel’s stability of compounded formulations contain?

A
  • properties (solubility, pH, pKa)
  • general stability considerations
  • stability reports of compounded products
  • commercial availability
25
Q

What are the NZ standards and guidelines regarding extemporaneous compounding?

A

-under MA 26: pharmacists may sell, supply compounded medicines without a manufacturing license if a request is made by the person to whom the medicine is to be sold or supplied

  • no GMP obligation
  • requirement to meet professional standards
  • requirement to comply with pharmacy services standard
26
Q

What are the professional standards that extemporaneous compounding must meet?

A

-competence standard 7: preparation of pharmacuetical products in community and hospital pharmacies

27
Q

What is the pharmacy services standard 2010 that extemporaneous compounding must comply to?

A

-section 5: dispensing, compounding, repackaging and batch preparation

28
Q

What is the importance of the pharmacy services standard 2010?

A
  • foundation for describing good practice and promoting continuous quality improvement
  • aims to ensure consumers receive safe and appropriate services
  • applicable to preparation of a medicine for an individual person in sufficient quantity to fulfil an individual prescription
  • also applies to small scale batch preparation in quantities that do not exceed those specified.
29
Q

What are the NZ compounding standards?

A
  • quality management
  • good compounding, repackaging and batch preparation practice
  • SOPs
  • internal audit for QC
  • documentation for QC
  • procedures for QC
  • materials and product release
  • staffing requirements
  • training
  • personal hygiene

Pharm304 (21 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions